1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals. Their findings will be presented at the 29th annual San Antonio Breast Cancer Symposium on Saturday, Dec. 16 (Abstract 4044).
"These data are very concerning because hormonal therapy for breast cancer is one of the most effective treatments in all of oncology," said Ann Partridge, MD, MPH, the study's lead author and a breast cancer specialist at Dana-Farber. "Women may be compromising their care, and ultimately their survival, if they do not take these medications as recommended."
Partridge and her colleagues analyzed claims data from three large commercial health plan systems to gauge treatment compliance of more than 7,000 women with early stage-breast cancer who, in addition to their regular treatment, began taking anastrozole.
Anastrozole is part of a new class of drugs, called aromatase inhibitors, that reduces the production of the hormone estrogen by blocking aromatase, an enzyme that converts the hormone androgen into estrogen. Studies have shown that lowering estrogen levels in post-menopausal women with hormone receptor-positive breast cancer can reduce their risk of disease recurrence.
In one of the health plans analyzed, the researchers found that 85 percent (1,275) of the women were still filling their prescriptions a year after anastrozole was first prescribed, but not everyone was doing so on a regular basis. The researchers also looked at the prescription filling habits of the 1,111 women who had been enrolled in the health plan for 12 consecutive months. They determined that, due to inconsistent refills, 19 percent of the women (211) had access to the drug less than 80 percent of the 12-month period after they first filled an anastrozole prescription. These women were considered to be non-adherent to the treatment.
"This study confirms that even patients with cancer may be non-adherent to their treatment," said Partridge, who is also an assistant professor of medicine at Harvard Medical School. "Non-adherence is a very complex issue, and the reasons that a patient may not take her medication as directed can include fear of or the experience of side effects, cost of treatment, and negative health beliefs, like the treatment will not help."
Bill Schaller | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...